Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs NetEase Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while NetEase Inc trades at $124.27 (market cap $76.09B). The key difference: NetEase Inc is far larger — about 6× Halozyme Therapeutics Inc. Common Stock's market cap, and NetEase Inc pays a 2.45% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and NetEase Inc for 73 Days on average.
| HALO | NTES | |
|---|---|---|
Market Cap | $12.58B | $76.09B |
Volume | 2,179,278 | 486,447 |
Sector | Health | Technology |
52-Week High | $115.22 | $152.85 |
52-Week Low | $61.63 | $109.26 |
Typical Hold Time | 1 Days | 73 Days |
Enterprise Value | $14.49B | $51.81B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NTES trades at $124.24, up 3.01% today, with a neutral technical signal and bearish moving averages. The stock shows strong fundamentals with a P/E of 15.92, net income margin of 27.88%, and robust cash flow from operations of $50.74 billion in 2025. Recent earnings were mixed, with a Q2 2026 miss but a Q1 2026 beat. Analyst consensus is strongly bullish with an $168 price target. News highlights focus on earnings results and long-term dividend growth potential.
The outlook for NTES is positive, supported by strong profitability, a healthy balance sheet, and analyst optimism. Key opportunities include revenue growth and AI investments, while risks involve earnings volatility and competitive pressures in the gaming sector. The stock presents a compelling case for growth investors seeking exposure to China's tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
